[ad_1]
The European Union will buy 300 million doses of the vaccine from Pfizer and Biontech, the president of the European Commission said on Monday after the two companies said that ninety percent of the experimental vaccine they developed could be effective against the new type. of coronavirus.
Ursula von der Leyen announced that an agreement would soon be signed with the two companies to purchase the vaccines. The chairman of the Brussels board added that until the vaccine is available, people should take precautions and take care of each other.
Good news from @pfizer Y @BioNTech_Group on the successful results of your latest clinical trial for a # COVID-19 vaccine. European science works!@EU_Commission to soon sign a contract with them for up to 300 million doses.
In the meantime, let’s continue to protect each other.
– Ursula von der Leyen (@vonderleyen) November 9, 2020
200 million doses will be obtained first
The committee held informational discussions with several pharmaceutical companies, including Pzifer-Biontech, months ago. The panel was informed in September that a planned contract based on the joint EU procurement would allow all EU member states to purchase the vaccine, as well as:
low- and middle-income countries to receive it as a donation.
The executive body of the Union is expected to provide, on behalf of all EU Member States, a framework contract for the first 200 million lots and the possibility of another 100 million lots.
Preliminary market commitments are made with manufacturers
The EU adopted its so-called European Vaccine Strategy in mid-June, which aims to provide high-quality, safe, effective and affordable vaccines to all European citizens within 12 to 18 months.
To this end, the Committee, together with the Member States, will make ex ante market commitments with vaccine manufacturers.
[ad_2]
